Navigation Links
Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
Date:7/11/2013

rmal and cancerous cells, so targeting integrins for stopping the growth of cancer is not a promising strategy. What is unique about asTF is that it binds to integrins on vessel-forming cells, activating them. We've shown that certain cancer cells share those same qualities, so if you target asTFwhich is elevated in cancerthere is significant potential to spare the 'good' parts of the cellular system while removing the 'bad' cancer-specific protein from the game," explains Bogdanov.

"Many routine therapies such as chemotherapy or radiation may not always be efficient. Targeting asTF in tumors using our monoclonal antibody may form a potent additional anticancer strategy in combination with conventional avenues", says Versteeg.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Mechanism found connecting metastatic breast cancer and arthritis
2. Cancerous tumors deliver pro-metastatic information in secreted vesicles
3. Should high-dose interleukin-2 continue to be the treatment of choice for metastatic melanoma?
4. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
5. Thomas Jefferson University researchers discover new pathways that drive metastatic prostate cancer
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Modulating the immune system to combat metastatic cancer
8. How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
9. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
10. Commonly used diabetes drug may help to prevent primary liver cancer
11. Biology professor secures grant to save West Virginias primary natural history collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics ... its new website design. "When we launched FindBiometrics ... Peter O,Neill , founder and CEO of FindBiometrics. "Now ... involvement from the key players on a very broad scale.  ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... San Diego, Calif. Glioblastoma, the most common and lethal ... because the tumors rapidly become resistant to therapy. As cancer ... growth and drug resistance, they are discovering molecular pathways that ... deadly cancer. Scientists at the Ludwig Institute for Cancer ...
... at the Society of Toxicology,s Annual Meeting and ToxExpo ... that have received growing public attention over the past ... explore how the development of an epidemiological database that ... risk assessment of arsenic in food. While epidemiological studies ...
... Vision and Ophthalmology 2013 Annual Meeting will feature lectures ... the organization,s five-day conference, May 5 9 in ... Series will include Oliver Smithies, DPhil; Roger Tsien, PhD ... University of North Carolina at Chapel Hill, is a ...
Cached Biology News:Novel combination therapy shuts down escape route, killing glioblastoma tumor cells 2Scientists explore topical health issues at meeting in Texas 23 distinguished keynote speakers to present during ARVO 2013 Annual Meeting 2
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... WALTHAM, Mass., Nov. 10, 2011 Interleukin Genetics, Inc. ... the third quarter ended September 30, 2011. Total ... $765,000, compared to $545,000 for the same period in the ... revenue. Research and development expenses were $325,000 ...
... Inc., a global, full-service testing laboratory with more than ... organs, cells, tissues and implantable biologic products and devices, ... private companies, as judged by the annual ColoradoBiz ... Top 250 Private Companies list is an annual ranking ...
... England Biolabs (NEB), in its continuing commitment to open ... database covering DNA polymerase biochemistry, genetics and structural biology. ... and maintained by NEB), Polbase summarizes the information that ... it easy for researchers to interrogate and use. Polbase ...
Cached Biology Technology:Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4LABS, Inc. Among Colorado's Top Private Companies 2New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers 2
... , Ultima II Series ... Ultima II represents the finest, most enhanced ... and blood bank configurations, each Ultima II ... system with built-in voltage boost and surge ...
...
Verotoxin IIbeta (457)...
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: